Ketorolac is a nonsteroidal anti-inflammatory drug used to manage moderately severe acute pain in adults.
The FDA said Jan. 8 that giving patients an injectable drug that contains particulate matter could obstruct blood vessels, resulting in local irritation of blood vessels, injection-site swelling, a mass of tissue that could become inflamed and infected, blood clots traveling to the lung, scarring of lung tissues and allergic reactions that could lead to life-threatening consequences.
No adverse events have been reported to the drugmaker.
Fresenius Kabi, based in Germany, is asking its customers and distributors to check their stocks and quarantine and discontinue use of the affected drugs.
Find the full news release here.
More articles on pharmacy:
Gilead testing remdesivir against new COVID-19 variants
Warp Speed giving some hospitals faulty syringes for COVID-19 vaccine doses
CVS Health names new chief people officer
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
